Article
Clinical Implications of Mismatch Repair Deficiency in Prostate Cancer
25 Jun 2019
Abstract excerpt
Immune checkpoint blockade holds great promise in the treatment of solid tumors but has not yet been approved for use in advanced prostate cancer. This is largely due to the relatively modest response in clinical trials in unselected patients and the lack of available biomarkers to predict clinical benefit. Germline and somatic mismatch repair (MMR) gene deficiencies are more prevalent than previously thought,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
